INTRODUCTION AND OBJECTIVES: The combination of radical prostatectomy (RP), radiation therapy (RT) and androgen deprivation therapy (ADT) -triple therapy (TT) is reserved for prostate cancer patients of extremely high risk or with PSA recurrence after primary therapy. The combination of these 3 treatments has a significant negative impact upon sexual function. This analysis was conducted to define the effect of TT on long-term erectile function (EF).
INTRODUCTION AND OBJECTIVES: The combination of radical prostatectomy (RP), radiation therapy (RT) and androgen deprivation therapy (ADT) -triple therapy (TT) is reserved for prostate cancer patients of extremely high risk or with PSA recurrence after primary therapy. The combination of these 3 treatments has a significant negative impact upon sexual function. This analysis was conducted to define the effect of TT on long-term erectile function (EF).
METHODS: Study population consisted of patients who (i) were exposed to TT (in any order) (ii) had baseline EF assessed by erection hardness score (EHS) (iii) were at least 6 months after completion of ADT (iv) had an early morning serum total testosterone level !6 months (m) after ADT completion and (v) had erectile function assessed (EHS, IIEF) at last follow-up visit. At !6m after ADT cessation, patients used maximum dose PDE5 inhibitor (PDE5i) on 4 occasions. If they failed they moved directly to penile injection therapy. Injection therapy was deemed to have failed if patients had been titrated to 100 units of trimix (papaverine/phentolamine/PGE1) without success. Multivariable analysis was performed to define predictors of penetration hardness erections with penile injections. Factors analyzed in the model included: patient age, baseline EF, ADT duration, nerve sparing status at RP and end-of-treatment (EOT) total testosterone RESULTS: 436 men met the inclusion criteria. Mean age 68AE11 years. Gleason scores: 7 68%, 8 19%, 9 13%. Nerve sparing status at RP: unilateral 12%, non-nerve sparing 88%. RT modality: 3Dconformal 17%, IMRT 51%, brachytherapy 32%. Baseline median EHS score was 3, with 7% grade 2 64% grade 3, 29% grade 4. Mean ADT duration was 9AE11 (4-28) months. Mean duration at last visit since cessation of ADT (last dose plus wash-out period) was 9AE5 months. Mean total testosterone level at last visit 262AE317 (86-742 ng/dl). 6% of men responded to PDE5i while only 49% responded to penile injections. At EOT on injections: median EHS was 2 with no patient achieving a grade 4 erection; mean IIEF EFD score was 14AE9 (4-24). Predictors of injection response are listed in the Table. CONCLUSIONS: Triple therapy for prostate cancer has a devastating effect on erectile function with more than half of the patients failing to respond to penile injection therapy. METHODS: Men with ED who had failed maximum dose PDE5 inhibitor agents; were enrolled in our IC program for !12 months (m); men treated with radiation therapy (RT) alone were compared to men who had had RT combined with ADT (and were still using ADT). 12 month follow-up or longer was required to be included in the analysis. Demographic, comorbidity, sexual function and sexual activity data were recorded. IC compliance was defined as use of IC !1/month and patients were followed at 3 months (m), 6m and 12 months after initial in-office IC training. Multivariable analysis was performed to define predictors of continued use of IC at 12 m after training completion.
RESULTS: 410 men were included: 216 RT alone, 194 RT+ADT. Mean age 67AE14 years; RT type was IMRT 226, brachytherapy 184; 82% of men were partnered (no difference between groups in any of these 3 factors). IC compliance for RT alone and RT+ADT groups was: @3m 84% vs 41%; @6m 76% vs 22%; @12m 81% vs 10% (all p<0.01). Predictors of IC compliance at 12 m after training are listed in Table. CONCLUSIONS: RT patients exposed to ADT struggle to comply with IC therapy despite understanding the role it might play in erectile rehabilitation of such patients. Younger, partnered and historically sexually active men were more likely to continue injection therapy long-term. . 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1347
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